GLP-1 for Menopause Weight Gain in Malaysia: Does It Work?

Weight gain during and after menopause is one of the most common health concerns among Malaysian women in their 40s and 50s. Hormonal changes reduce metabolic rate and shift fat distribution towards the abdomen, often despite no change in diet or exercise habits. GLP-1 medications are proving to be a powerful tool for managing menopause-related weight changes, with effects that go beyond simple calorie reduction.

Why Does Weight Gain Happen During Menopause?

As oestrogen levels decline during perimenopause and menopause, fat distribution in the body undergoes a significant shift. Fat that was previously stored preferentially in the hips and thighs begins to accumulate in the abdomen, particularly as visceral fat, which surrounds internal organs and is strongly associated with metabolic disease risk.

Oestrogen also plays a role in preserving muscle mass. As it declines, muscle loss accelerates. Since muscle tissue burns more calories at rest than fat tissue, this reduces resting metabolic rate. Many women find they gain weight during menopause even when their diet and exercise habits have not changed, because their bodies are burning fewer calories than before.

Malaysian women face additional challenges. Genetic predisposition to central adiposity and insulin resistance means that the metabolic consequences of menopause-related fat redistribution can be particularly significant. The risk of developing type 2 diabetes, hypertension, and cardiovascular disease rises meaningfully after menopause, making weight management during this life stage a genuine medical priority.

How GLP-1 Addresses Menopause-Related Weight Gain

GLP-1 medications act on appetite-regulating pathways in the brain independently of oestrogen levels. This means that unlike some dietary approaches that become less effective as hormone levels change, GLP-1 medications retain their appetite-suppressing effects regardless of menopausal status.

Clinical data consistently shows that GLP-1 treatment preferentially reduces visceral fat, the abdominal fat that accumulates most aggressively during menopause and poses the greatest metabolic risk. This is particularly valuable for menopausal women, as reducing visceral fat improves insulin sensitivity, blood pressure, and lipid profiles.

GLP-1 medications also improve insulin sensitivity directly, addressing one of the key metabolic changes that accelerates during menopause. Improved insulin sensitivity helps the body process glucose more efficiently, reducing the tendency toward fat storage that accompanies insulin resistance.

What Do the Clinical Studies Show?

The STEP 1 trial, which enrolled 1,961 patients for 68 weeks, included a substantial proportion of post-menopausal women. Subgroup analyses from this and related trials show that post-menopausal women achieve weight loss outcomes comparable to pre-menopausal women, typically 10-15% of body weight, demonstrating that menopausal status does not impair GLP-1 efficacy.

Some observational evidence and patient reports suggest that GLP-1 treatment may have mild beneficial effects on certain menopausal symptoms, particularly those linked to weight and metabolic factors such as sleep disruption, joint pain, and mood changes associated with metabolic dysfunction. These effects are secondary to weight loss and metabolic improvement, not a direct action of GLP-1 on hormonal pathways.

What to Expect: Results Timeline

Individual outcomes vary depending on starting weight, adherence, lifestyle factors, and overall health. Women taking hormone replacement therapy (HRT) concurrently with GLP-1 treatment generally achieve comparable results. HRT does not interfere with GLP-1 efficacy, and the two treatments can be used together safely under physician supervision.

Does GLP-1 Interact with HRT?

There are no known clinically significant drug interactions between GLP-1 medications (semaglutide, liraglutide) and standard hormone replacement therapy regimens, including oestrogen and progesterone formulations. Women who are already using HRT for menopausal symptom management can generally add GLP-1 treatment without concern about pharmacological interactions.

As with all multi-medication regimens, it is important that your prescribing physician is aware of all medications you are taking, including HRT, supplements, and over-the-counter treatments. At Seimbang, our assessment process captures your complete medication history to ensure safe and appropriate prescribing.

Is GLP-1 Right for Me as a Malaysian Woman in Menopause?

GLP-1 treatment is generally appropriate for women in menopause or perimenopause who have a BMI of 27.5 or above with at least one weight-related metabolic risk factor, such as pre-diabetes, hypertension, or elevated cholesterol, or a BMI of 30 or above. The reduced oestrogen environment of menopause does not reduce GLP-1 efficacy.

At Seimbang, our female-led medical team conducts a comprehensive eligibility assessment that takes into account your menopausal status, hormonal medications, and specific metabolic risk profile. We design personalised treatment plans that consider the full hormonal and metabolic picture, not just a single number on the scale.

Frequently Asked Questions